Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Aytu Biopharma (AYTU) Operating Income: 2009-2025

Historic Operating Income for Aytu Biopharma (AYTU) over the last 17 years, with Sep 2025 value amounting to -$1.5 million.

  • Aytu Biopharma's Operating Income fell 61.72% to -$1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.4 million, marking a year-over-year decrease of 274.71%. This contributed to the annual value of -$7.8 million for FY2025, which is 259.20% down from last year.
  • Per Aytu Biopharma's latest filing, its Operating Income stood at -$1.5 million for Q3 2025, which was up 80.27% from -$7.6 million recorded in Q2 2025.
  • In the past 5 years, Aytu Biopharma's Operating Income registered a high of $3.1 million during Q4 2023, and its lowest value of -$53.4 million during Q1 2022.
  • In the last 3 years, Aytu Biopharma's Operating Income had a median value of -$1.5 million in 2025 and averaged -$1.8 million.
  • Its Operating Income has fluctuated over the past 5 years, first slumped by 1,792.90% in 2024, then surged by 251.60% in 2025.
  • Aytu Biopharma's Operating Income (Quarterly) stood at -$11.3 million in 2021, then soared by 39.19% to -$6.9 million in 2022, then skyrocketed by 145.81% to $3.1 million in 2023, then crashed by 153.88% to -$1.7 million in 2024, then crashed by 61.72% to -$1.5 million in 2025.
  • Its Operating Income was -$1.5 million in Q3 2025, compared to -$7.6 million in Q2 2025 and $2.4 million in Q1 2025.